Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Inclusion Criteria

• Is a cancer patient enrolled in the Cancer Patient Immune Response to COVID-19 Vaccine Study (MCC 21138) or who has completed the two mRNA-1273 vaccine series prior to March 31, 2021
• Understands, agrees, and is able to comply with the study procedures and provides written informed consent
• Is an adult, at least 18 years of age
• Has no known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients
• Has not received more or less than 2 doses of mRNA-1273 vaccine

Exclusion Criteria

• Is acutely ill or febrile 24 hours prior to or at the day 1 visit. Fever is defined as a body temperature >= 38.0 degree Celsius >= 100.4 degree Fahrenheit. Participants who meet this criterion may have the day 1 visit rescheduled
• Has current treatment with investigational agents for either prophylaxis against COVID-19 or treatment of COVID-19 (eg, anti-SARS-CoV-2 monoclonal antibodies)
• Has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically: * Active symptoms of COVID-19 infection at the time of consent (e.g., fever, loss of taste and smell, etc.) * Bleeding disorder that is considered a contraindication to intramuscular route of administration (IM) injection or phlebotomy * Dermatologic conditions that could affect local solicited AR assessments * Known or suspected allergy or history of anaphylaxis, urticaria, or other significant AR to the vaccine or its excipients
• Has received: * Any non-study vaccine within 14 days before or after any dose of vaccine * More or less than 2 doses of mRNA-1273 vaccine